The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.
For active New Orleanians, knee osteoarthritis (OA) pain can sideline even the most passionate participants. Whether it’s ...